Selected article for: "acute aki kidney injury and admission outcome"

Author: ÖZTÜRK, Savaş; TURGUTALP, Kenan; ARICI, Mustafa; ÇETİNKAYA, Hakkı; ALTIPARMAK, Mehmet Rıza; AYDIN, Zeki; SOYPAÇACI, Zeki; BORA, Feyza; KARA, Ekrem; CEBECİ, Egemen; ÖZLER, Tuba Elif; DÖLARSLAN, Mürşide Esra; SİPAHİ, Savaş; AYAR, Yavuz; ŞAHİN, İdris; BAKIRDÖĞEN, Serkan; İSLAM, Mahmud; GÖRGÜLÜ, Numan; ÖĞÜTMEN, Melike Betül; ŞENGÜL, Erkan; GÜNGÖR, Özkan; SEYAHİ, Nurhan; TOKGÖZ, Bülent; ODABAŞ, Ali Rıza; TONBUL, Halil Zeki; SEZER, Siren; YILDIZ, Alaattin; ATEŞ, Kenan
Title: Impact of hospital-acquired acute kidney injury on Covid-19 outcomes in patients with and without chronic kidney disease: a multicenter retrospective cohort study
  • Cord-id: e7wmq3ff
  • Document date: 2021_6_28
  • ID: e7wmq3ff
    Snippet: BACKGROUND/AIM: Hospital-acquired acute kidney injury (HA-AKI) may commonly develop in Covid-19 patients and is expected to have higher mortality. There is little comparative data investigating the effect of HA-AKI on mortality of chronic kidney disease (CKD) patients and a control group of general population suffering from Covid-19. MATERIALS AND METHODS: HA-AKI development was assessed in a group of stage 3–5 CKD patients and control group without CKD among adult patients hospitalized for Co
    Document: BACKGROUND/AIM: Hospital-acquired acute kidney injury (HA-AKI) may commonly develop in Covid-19 patients and is expected to have higher mortality. There is little comparative data investigating the effect of HA-AKI on mortality of chronic kidney disease (CKD) patients and a control group of general population suffering from Covid-19. MATERIALS AND METHODS: HA-AKI development was assessed in a group of stage 3–5 CKD patients and control group without CKD among adult patients hospitalized for Covid-19. The role of AKI development on the outcome (in-hospital mortality and admission to the intensive care unit [ICU]) of patients with and without CKD was compared. RESULTS: Among 621 hospitalized patients (age 60 [IQR: 47–73]), women: 44.1%), AKI developed in 32.5% of the patients, as stage 1 in 84.2%, stage 2 in 8.4%, and stage 3 in 7.4%. AKI developed in 48.0 % of CKD patients, whereas it developed in 17.6% of patients without CKD. CKD patients with HA-AKI had the highest mortality rate of 41.1% compared to 14.3% of patients with HA-AKI but no CKD (p < 0.001). However, patients with AKI+non-CKD had similar rates of ICU admission, mechanical ventilation, and death rate to patients with CKD without AKI. Adjusted mortality risks of the AKI+non-CKD group (HR: 9.0, 95% CI: 1.9–44.2) and AKI+CKD group (HR: 7.9, 95% CI: 1.9–33.3) were significantly higher than that of the non-AKI+non-CKD group. CONCLUSION: AKI frequently develops in hospitalized patients due to Covid-19 and is associated with high mortality. HA-AKI has worse outcomes whether it develops in patients with or without CKD, but the worst outcome was seen in AKI+CKD patients.

    Search related documents:
    Co phrase search for related documents
    • adjusted mortality and admission hospital mortality outcome: 1, 2, 3, 4, 5, 6, 7
    • adjusted mortality risk and admission hospital mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13